Crinecerfont in a First Clinical Application of a CRH Antagonist: Further Potential Uses Are Still an Open Chapter!-Reference-Cited by-同舟云学术

Crinecerfont in a First Clinical Application of a CRH Antagonist: Further Potential Uses Are Still an Open Chapter!

Published:2023-08-31 Issue: Volume: Page:
ISSN:0021-972X
Container-title:The Journal of Clinical Endocrinology & Metabolism
language:en
Short-container-title:

Author:

Chrousos George P¹^ORCID

Affiliation:

1. University Research Institute of Maternal and Child Health and Precision Medicine and UNESCO Chair on Adolescent Health Care, National and Kapodistrian University of Athens , Athens 11527 , Greece

Publisher

The Endocrine Society

Subject

Biochemistry (medical),Clinical Biochemistry,Endocrinology,Biochemistry,Endocrinology, Diabetes and Metabolism

Link

https://academic.oup.com/jcem/advance-article-pdf/doi/10.1210/clinem/dgad513/51374379/dgad513.pdf

Reference8 articles.

1. Functional characteristics of CRH receptors and potential clinical applications of CRH-receptor antagonists;Grammatopoulos;Trends Endocrinol Metab,2002

2. Potential uses of corticotropin-releasing hormone antagonists;Zoumakis;Ann N Y Acad Sci,2006

3. Crinecerfont lowers elevated hormone markers in adults with 21-hydroxylase deficiency congenital adrenal hyperplasia;Auchus;J Clin Endocrinol Metab,2022

4. Crinecerfont, a CRF1 receptor antagonist, lowers adrenal androgens in adolescents with congenital adrenal hyperplasia;Newfield;J Clin Endocrinol Metab,2023

5. Congenital adrenal hyperplasia;Auer;Lancet,2023

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Design, Synthesis, and Biological Evaluations of Novel Thiazolo[4,5-d]pyrimidine Corticotropin Releasing Factor (CRF) Receptor Antagonists as Potential Treatments for Stress Related Disorders and Congenital Adrenal Hyperplasia (CAH);Molecules;2024-08-01